News
GALT
2.390
-0.83%
-0.020
Galectin Therapeutics Inc reports results for the quarter ended in December - Earnings Summary
Galectin Therapeutics Inc reported a quarterly adjusted loss of 16 cents per share for the quarter ended in December. The company's reported revenue was zero; analysts expected zero. The average analyst rating on the company's shares is "buy" shares had risen by 45.2% this quarter.
Reuters · 21m ago
Galectin Therapeutics GAAP EPS of -$0.74
Galectin Therapeutics has $25.7 million in cash and cash equivalents as of December 31, 2023. The company believes it has sufficient cash to fund operations through March 31, 2025. Galectin expects to report FY GAAP EPS of -$0.74.
Seeking Alpha · 38m ago
*Galectin Therapeutics 2023 Research and Development Expenses $32.1M >GALT
Dow Jones · 1h ago
*Galectin Therapeutics 2023 Loss/Shr 74c >GALT
Dow Jones · 1h ago
Press Release: Galectin Therapeutics Reports 2023 Financial Results and Provides Business Update
Galectin Therapeutics reports 2023 Financial Results and Provides Business Update for the year ended December 31, 2023. Galectin is the leading developer of therapeutics that target galectin proteins. The company is focused on advancing its belapectin program for the treatment of liver cirrhosis and portal hypertension. The drug targets a critical protein in the pathogenesis of NASH.
Dow Jones · 1h ago
Press Release: Galectin Therapeutics Reports 2023 -2-
Galectin Therapeutics and its associated logo is a registered trademark. Belapectin is the USAN assigned name for Galectin's galectin-3 inhibitor bel apectin. The company's net loss for the year ended December 31, 2013 was $38,072. Galect in Therapeutic Inc. Has a net loss of $8.2 million for the quarter.
Dow Jones · 1h ago
Weekly Report: what happened at GALT last week (0318-0322)?
Weekly Report · 4d ago
Galectin: Q4 2024 NASH Cirrhosis Data Readout Is A Major Inflection Point
Galectin Therapeutics is gearing up to report topline results from the phase 2b/3 NAVIGATE study in Q4 of 2024. The study is exploring the use of Belapectin for the prevention of esophageal varices in patients with NASH cirrhosis. Galectin has a major milestone approaching towards the end of 2024 with the release of data from the study.
Seeking Alpha · 03/21 00:11
Inventiva Phase 2 study for MASH drug meets primary endpoint
Inventiva Phase 2 study for MASH drug meets primary endpoint. Inventiva's drug candidate lanifibranor met its primary efficacy endpoint in the treatment of patients with MASH/NASH and type 2 diabetes. Last week, Madrigal drug Rezdiffra became the first FDA-approved treatment for the liver disorder.
Seeking Alpha · 03/18 21:45
Weekly Report: what happened at GALT last week (0311-0315)?
Weekly Report · 03/18 12:24
NASH drug market expected to surpass $48B by 2035
Healthcare NASH drug market expected to surpass $48B by 2035. Global therapeutic market catering to the widely prevalent liver disease non-alcoholic steatohepatitis is projected to reach $48.3B. North America is set to generate the lion's share of revenue. Europe is anticipated to record the highest CAGR in the NASH treatment market. Madrigal Pharmaceuticals received FDA approval for first U.S.-approved NASH therapy.
Seeking Alpha · 03/16 16:57
Madrigal climbs amid hopes for new NASH drug; B. Riley upgrades
FDA approves Madrigal Pharmaceuticals' new drug for nonalcoholic steatohepatitis. Rezdiffra is the first U.S.-approved therapy for NASH. B. Riley upgrades the company's stock to Neutral from Sell. The company's shares are up 26% in the premarket.
Seeking Alpha · 03/15 12:19
Madrigal granted FDA approval for NASH therapy
Madrigal Pharmaceuticals' lead asset resmetirom is the first U.S.-approved therapy for a liver condition called nonalcoholic steatohepatitis. The drug will be indicated with diet and exercise for NASH with moderate to advanced liver fibrosis. Madrigal granted FDA approval for NASh therapy for March 14, 2024.
Seeking Alpha · 03/14 19:45
Madrigal and liver drug developers fall ahead of FDA decision on NASH therapy
Madrigal and liver drug developers fall ahead of FDA decision on NASH therapy. Companies focused on developing drugs for a liver disease called nonalcoholic steatohepatitis are among the notable decliners. Madrigal Pharmaceuticals' lead asset, resmetirom, is targeted at NASH.
Seeking Alpha · 03/14 14:42
Liver drug developers outperform as U.S. awaits first NASH drug
Liver drug developers outperform as U.S. Awaits first NASH drug approval. Madrigal Pharmaceuticals awaits FDA clearance for its lead asset resmetirom. The company's shares have soared 16% this year, outperforming the biopharma industry.
Seeking Alpha · 03/13 17:29
*Galectin Therapeutics Appoints Khurram Jamil, M.D. as Vice Pres, Clinical Development
Dow Jones · 03/12 12:01
Press Release: Galectin Therapeutics Expands Clinical Team with the Appointment of Khurram Jamil, M.D. as Vice President, Clinical Development
Galectin Therapeutics Expands Clinical Team with the Appointment of Khurram Jamil, M.D. As Vice President, Clinical Development. Dr. Jamil brings to Galectin almost two decades of experience in clinical development across the biotechnology industry.
Dow Jones · 03/12 12:00
Weekly Report: what happened at GALT last week (0304-0308)?
Weekly Report · 03/11 12:18
Weekly Report: what happened at GALT last week (0226-0301)?
Weekly Report · 03/04 12:23
Weekly Report: what happened at GALT last week (0219-0223)?
Weekly Report · 02/26 12:44
More
Webull provides a variety of real-time GALT stock news. You can receive the latest news about Galectin Therapeutics Inc through multiple platforms. This information may help you make smarter investment decisions.
About GALT
Galectin Therapeutics Inc. is a clinical-stage biotechnology company. The Company is engaged in drug research and development to create new therapies for fibrotic disease, cancer and selected other diseases. The Company’s drug candidates are based on its method of targeting galectin proteins, which are key mediators of biologic and pathologic functions. The Company’s product candidates include galectin-3 inhibitor, which is a belapectin and GM-CT-01. The Company’s lead drug belapectin is a carbohydrate-based drug that inhibits the galectin-3 protein which is directly involved in multiple inflammatory, fibrotic, and malignant diseases. The Company is using a galectin-3 inhibitor to treat advanced liver fibrosis and liver cirrhosis in non-alcoholic steatohepatitis (NASH) patients. The Company also designed a Phase IIb/III clinical study, the NAVIGATE trial, evaluating the safety and efficacy of its galectin-3 inhibitor, belapectin, for the prevention of esophageal varices.